Advertisement

Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis

  • Augustine Chung
  • James English
  • Elizabeth R. VolkmannEmail author
Scleroderma (C Denton, Section Editor)
  • 7 Downloads
Part of the following topical collections:
  1. Topical Collection on Scleroderma

Abstract

Purpose of review

Systemic sclerosis (SSc) has the highest cause–specific mortality of all the connective tissue diseases, and interstitial lung disease (ILD) is the number one cause of death among patients with SSc.

Recent findings

Historically, therapeutic agents with widespread immunosuppressive effects have been used to treat SSc-ILD. However, data from recent landmark clinical trials in SSc-ILD have affirmed the prior observation that SSc-ILD is a uniquely heterogenous disease with marked variations in rates of response to immunosuppressive therapy. In the last few years, innovative research studies have advanced our understanding of the pathophysiology of SSc-ILD and stimulated interest in the development of novel candidate therapeutics with potential disease–modifying properties for SSc-ILD. Anti-fibrotics are a new class of drugs that may change our approach to the treatment of SSc-ILD similar to the paradigm shift that occurred for the treatment of idiopathic pulmonary fibrosis (IPF). The present review describes the most recent advances in our understanding of SSc-ILD in the context of lessons learned from the study of IPF.

Summary

The article concludes with an outline of the most important unanswered questions in SSc-ILD research that could help inform future research efforts in this area.

Keywords

Systemic sclerosis Interstitial lung disease Treatment Immunosuppression Idiopathic pulmonary fibrosis 

Notes

Funding

The author, ERV, received financial support from the Rheumatology Research Foundation.

Compliance with Ethical Standards

Conflict of Interest

Augustine Chung and James English declare that they have no conflict of interest.

Dr. Volkmann reports personal fees from Boehringer Ingelheim, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.  https://doi.org/10.1136/ard.2009.114264.CrossRefPubMedGoogle Scholar
  2. 2.
    American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.  https://doi.org/10.1164/ajrccm.161.2.ats3-00.CrossRefGoogle Scholar
  3. 3.
    Showalter K, Hoffmann A, Rouleau G, Aaby D, Lee J, Richardson C, et al. Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis. J Rheumatol. 2018;45(11):1572–6.  https://doi.org/10.3899/jrheum.171362.CrossRefPubMedGoogle Scholar
  4. 4.
    Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TDL, Maurer B, Jordan S, et al. Pulmonary function tests: high rate of false negatives in the early detection and screening of scleroderma interstitial lung disease. Swiss Med Wkly. 2015;145:9S-S.Google Scholar
  5. 5.
    Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9):1789–801.PubMedGoogle Scholar
  6. 6.
    De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005;6:96.  https://doi.org/10.1186/1465-9921-6-96.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.  https://doi.org/10.1136/ard.2006.062901.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet. 1991;338(8768):661–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Gilchrist FC, Bunn C, Foley PJ, Lympany PA, Black CM, Welsh KI, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2001;2(2):76–81.  https://doi.org/10.1038/sj.gene.6363734.CrossRefPubMedGoogle Scholar
  10. 10.
    Mayes MD. Scleroderma epidemiology. Rheum Dis Clin N Am. 2003;29(2):239–54.CrossRefGoogle Scholar
  11. 11.
    Alba MA, Velasco C, Simeon CP, Fonollosa V, Trapiella L, Egurbide MV, et al. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore). 2014;93(2):73–81.  https://doi.org/10.1097/MD.0000000000000018.CrossRefGoogle Scholar
  12. 12.
    Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003.  https://doi.org/10.1056/NEJMra0806188.CrossRefPubMedGoogle Scholar
  13. 13.
    Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–72.  https://doi.org/10.1164/ajrccm.150.4.7921471.CrossRefPubMedGoogle Scholar
  14. 14.
    Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.  https://doi.org/10.1164/rccm.200602-163OC.CrossRefPubMedGoogle Scholar
  15. 15.
    Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(8):832–7.  https://doi.org/10.1164/rccm.200906-0959OC.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223–35.  https://doi.org/10.1016/j.semarthrit.2007.05.003.CrossRefPubMedGoogle Scholar
  17. 17.
    Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483–92.  https://doi.org/10.2147/CLEP.S54815.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–72.  https://doi.org/10.1016/S2213-2600(14)70101-8.CrossRefPubMedGoogle Scholar
  19. 19.
    Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003;5(2):160–7.CrossRefPubMedGoogle Scholar
  20. 20.
    McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007;57(2):318–26.  https://doi.org/10.1002/art.22532.CrossRefPubMedGoogle Scholar
  21. 21.
    Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9):2986–94.  https://doi.org/10.1002/art.34482.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Caminati A, Madotto F, Cesana G, Conti S, Harari S. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev. 2015;24(137):436–44.  https://doi.org/10.1183/16000617.0040-2015.CrossRefPubMedGoogle Scholar
  23. 23.
    Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–23.  https://doi.org/10.1056/NEJMra1705751.CrossRefPubMedGoogle Scholar
  24. 24.
    Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232(2):560–7.  https://doi.org/10.1148/radiol.2322031223.CrossRefPubMedGoogle Scholar
  25. 25.
    Jo HE, Glaspole IN, Levin KC, McCormack SR, Mahar AM, Cooper WA, et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology. 2016;21(8):1438–44.  https://doi.org/10.1111/resp.12850.CrossRefPubMedGoogle Scholar
  26. 26.
    Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904–10.  https://doi.org/10.1164/rccm.200402-147OC.CrossRefPubMedGoogle Scholar
  27. 27.
    Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(3):585–91.  https://doi.org/10.1183/09031936.00063706.CrossRefPubMedGoogle Scholar
  28. 28.
    Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.  https://doi.org/10.1164/rccm.201308-1483ST.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Thomson CC, Duggal A, Bice T, Lederer DJ, Wilson KC, Raghu G. 2018 clinical practice guideline summary for practicing clinicians: diagnosis of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2018.  https://doi.org/10.1513/AnnalsATS.201809-604CME.
  30. 30.
    De Sadeleer LJ, Meert C, Yserbyt J, Slabbynck H, Verschakelen JA, Verbeken EK, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest. 2018;153(6):1416–23.  https://doi.org/10.1016/j.chest.2018.03.026.CrossRefPubMedGoogle Scholar
  31. 31.
    Lafyatis R. Transforming growth factor beta--at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10(12):706–19.  https://doi.org/10.1038/nrrheum.2014.137.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim JB, Lee S, Kim HR, Park SY, Lee M, Yoon JH, et al. Transforming growth factor-beta decreases side population cells in hepatocellular carcinoma in vitro. Oncol Lett. 2018;15(6):8723–8.  https://doi.org/10.3892/ol.2018.8441.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Annes JP, Rifkin DB, Munger JS. The integrin alphaVbeta6 binds and activates latent TGFbeta3. FEBS Lett. 2002;511(1–3):65–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Henderson NC, Sheppard D. Integrin-mediated regulation of TGFbeta in fibrosis. Biochim Biophys Acta. 2013;1832(7):891–6.  https://doi.org/10.1016/j.bbadis.2012.10.005.CrossRefPubMedGoogle Scholar
  35. 35.
    Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65.  https://doi.org/10.1164/rccm.200706-805OC.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. Biochim Biophys Acta. 2013;1832(7):897–904.  https://doi.org/10.1016/j.bbadis.2012.06.008.CrossRefPubMedGoogle Scholar
  37. 37.
    Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:157.  https://doi.org/10.1186/s12931-014-0157-3.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki SI, Ueno T, et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung. 2010;188(3):247–52.  https://doi.org/10.1007/s00408-009-9223-x.CrossRefPubMedGoogle Scholar
  39. 39.
    Selman M, King TE, Pardo A, American Thoracic S, European Respiratory S, American College of Chest P. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–51.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Keogh BA, Crystal RG. Alveolitis: the key to the interstitial lung disorders. Thorax. 1982;37(1):1–10.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Reynolds HY, Merrill WW. Analysis of bronchoalveolar lavage in normal humans and patients with diffuse interstitial lung diseases. Biserte G, Chretien J, Viisiu C, eds Proceedings of an international Inserm symposium on bronchoalveolar lavage in man. 1979;84:227–50.Google Scholar
  42. 42.
    Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979;97(1):149–206.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1301–15.  https://doi.org/10.1164/ajrccm.157.4.9707039.CrossRefPubMedGoogle Scholar
  44. 44.
    Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.  https://doi.org/10.1038/nrdp.2017.74.CrossRefPubMedGoogle Scholar
  45. 45.
    Vancheri C. Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med. 2015;13:220.  https://doi.org/10.1186/s12916-015-0478-1.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kulkarni T, de Andrade J, Zhou Y, Luckhardt T, Thannickal VJ. Alveolar epithelial disintegrity in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L185–91.  https://doi.org/10.1152/ajplung.00115.2016.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013;229(2):298–309.  https://doi.org/10.1002/path.4104.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Yang IV, Pedersen BS, Rabinovich E, Hennessy CE, Davidson EJ, Murphy E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(11):1263–72.  https://doi.org/10.1164/rccm.201408-1452OC.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis. 1985;131(2):281–9.  https://doi.org/10.1164/arrd.1985.131.2.281.CrossRefPubMedGoogle Scholar
  50. 50.
    Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol. 1994;145(1):114–25.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.  https://doi.org/10.1056/NEJMoa055120.CrossRefPubMedGoogle Scholar
  52. 52.
    Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66(6):1625–35.  https://doi.org/10.1002/art.38390.CrossRefPubMedGoogle Scholar
  53. 53.
    Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589–98.  https://doi.org/10.1002/art.27224.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63(11):3540–6.  https://doi.org/10.1002/art.30548.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L, et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol. 2014;66(7):1900–8.  https://doi.org/10.1002/art.38623.CrossRefPubMedGoogle Scholar
  56. 56.
    Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M, Kwoh CK, et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2016;68(4):993–1003.  https://doi.org/10.1002/art.39490.CrossRefPubMedGoogle Scholar
  57. 57.
    Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 1999-2002 implications for patient care. J Clin Rheumatol. 2007;13(4):187–92.  https://doi.org/10.1097/RHU.0b013e318124a89e.CrossRefPubMedGoogle Scholar
  59. 59.
    Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69(7):1451–60.  https://doi.org/10.1002/art.40114.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    • Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019;78(1):122–30.  https://doi.org/10.1136/annrheumdis-2018-213708. This was the first study to assess long-term morbitidy and mortality outcomes in patients who participated in two of the largest clinical trials published to date in SSc-ILD.CrossRefPubMedGoogle Scholar
  61. 61.
    • Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69(8):1670–8.  https://doi.org/10.1002/art.40130. This study found that short-term declines in pulmonary function are important predictors of long-term mortality in SSc-ILD based on an observational cohort study.CrossRefPubMedGoogle Scholar
  62. 62.
    Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.  https://doi.org/10.7326/0003-4819-156-10-201205150-00004.CrossRefPubMedGoogle Scholar
  63. 63.
    Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999;160(3):899–905.  https://doi.org/10.1164/ajrccm.160.3.9903021.CrossRefPubMedGoogle Scholar
  64. 64.
    King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.  https://doi.org/10.1056/NEJMoa1402582.CrossRefPubMedGoogle Scholar
  65. 65.
    Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.  https://doi.org/10.1056/NEJMoa1402584.CrossRefPubMedGoogle Scholar
  66. 66.
    Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538–42.  https://doi.org/10.1164/rccm.200211-1311OC.CrossRefPubMedGoogle Scholar
  67. 67.
    Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084–90.  https://doi.org/10.1164/rccm.200302-219OC.CrossRefPubMedGoogle Scholar
  68. 68.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.  https://doi.org/10.1164/rccm.2009-040GL.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75.  https://doi.org/10.1164/rccm.201604-0801CI.CrossRefPubMedGoogle Scholar
  70. 70.
    Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–54.  https://doi.org/10.1164/rccm.200706-877OC.CrossRefPubMedGoogle Scholar
  71. 71.
    Hax V, Bredemeier M, Didonet Moro AL, Pavan TR, Vieira MV, Pitrez EH, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum. 2017;47(2):228–34.  https://doi.org/10.1016/j.semarthrit.2017.03.019.CrossRefPubMedGoogle Scholar
  72. 72.
    Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;52(1):155–60.  https://doi.org/10.1093/rheumatology/kes289.CrossRefGoogle Scholar
  73. 73.
    • Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.  https://doi.org/10.1136/annrheumdis-2016-209909. This was the first RCT to evaluate the efficacy of mycophenolate for the treatment of SSc-ILD. The results demonstrated that mycophenolate was safer an better tolerated compared with cyclophosphamide.CrossRefPubMedGoogle Scholar
  74. 74.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–19.  https://doi.org/10.1016/S2213-2600(16)30152-7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther. 2016;18(1):123.  https://doi.org/10.1186/s13075-016-1015-0.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. Ann Am Thorac Soc. 2018;15(11):1286–95.  https://doi.org/10.1513/AnnalsATS.201802-079OC.CrossRefPubMedGoogle Scholar
  77. 77.
    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.  https://doi.org/10.1002/art.38098.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35(6):1064–72.PubMedGoogle Scholar
  79. 79.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962–70.  https://doi.org/10.1002/art.22204.CrossRefPubMedGoogle Scholar
  80. 80.
    Sanges S, Guerrier T, Launay D, Lefevre G, Labalette M, Forestier A, et al. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne. 2017;38(2):113–24.  https://doi.org/10.1016/j.revmed.2016.02.016.CrossRefPubMedGoogle Scholar
  81. 81.
    Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–40.  https://doi.org/10.1016/S0140-6736(16)00232-4.CrossRefPubMedGoogle Scholar
  82. 82.
    Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3(4):330–8.  https://doi.org/10.1513/pats.200602-016TK.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.  https://doi.org/10.1056/NEJMoa1113354.CrossRefGoogle Scholar
  84. 84.
    Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009;28(10):1285–97.  https://doi.org/10.1038/onc.2008.479.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.  https://doi.org/10.1002/art.24186.CrossRefPubMedGoogle Scholar
  86. 86.
    Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003–9.  https://doi.org/10.1136/ard.2010.143974.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63(11):3547–51.  https://doi.org/10.1002/art.30549.CrossRefPubMedGoogle Scholar
  88. 88.
    Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, et al. Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. 2015;17:213.  https://doi.org/10.1186/s13075-015-0721-3.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Martyanov V, Kim GJ, Hayes W, Du S, Ganguly BJ, Sy O, et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One. 2017;12(11):e0187580.  https://doi.org/10.1371/journal.pone.0187580.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941–8.  https://doi.org/10.1136/annrheumdis-2016-210823.CrossRefPubMedGoogle Scholar
  91. 91.
    Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–62.  https://doi.org/10.1002/art.37988.CrossRefPubMedGoogle Scholar
  92. 92.
    Didiasova M, Singh R, Wilhelm J, Kwapiszewska G, Wujak L, Zakrzewicz D, et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J. 2017;31(5):1916–28.  https://doi.org/10.1096/fj.201600892RR.CrossRefPubMedGoogle Scholar
  93. 93.
    Xiao H, Zhang GF, Liao XP, Li XJ, Zhang J, Lin H, et al. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018;21(2):477–86.  https://doi.org/10.1111/1756-185X.13247.CrossRefPubMedGoogle Scholar
  94. 94.
    Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ. Review: Frontiers of Antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol. 2017;69(2):257–67.  https://doi.org/10.1002/art.39865.CrossRefPubMedGoogle Scholar
  95. 95.
    Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford). 2015;54(1):144–51.  https://doi.org/10.1093/rheumatology/keu288.CrossRefGoogle Scholar
  96. 96.
    Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–9.  https://doi.org/10.1183/09031936.00005209.CrossRefPubMedGoogle Scholar
  97. 97.
    Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.  https://doi.org/10.1016/S0140-6736(11)60405-4.CrossRefPubMedGoogle Scholar
  98. 98.
    Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.  https://doi.org/10.1016/S2213-2600(16)30326-5.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74–9.  https://doi.org/10.1016/j.rmed.2016.02.001.CrossRefPubMedGoogle Scholar
  100. 100.
    Gonzalez EG, Selvi E, Balistreri E, Akhmetshina A, Palumbo K, Lorenzini S, et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis. 2012;71(9):1545–51.  https://doi.org/10.1136/annrheumdis-2011-200314.CrossRefPubMedGoogle Scholar
  101. 101.
    del Rio C, Navarrete C, Collado JA, Bellido ML, Gomez-Canas M, Pazos MR, et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-gamma and CB2 pathways. Sci Rep. 2016;6:21703.  https://doi.org/10.1038/srep21703.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490–8.  https://doi.org/10.1001/jama.2014.6368.CrossRefPubMedGoogle Scholar
  103. 103.
    Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498–506.  https://doi.org/10.1016/S0140-6736(11)60982-3.CrossRefPubMedGoogle Scholar
  104. 104.
    Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35–47.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Arruda LCM, Malmegrim KCR, Lima-Junior JR, Clave E, Dias JBE, Moraes DA, et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Adv. 2018;2(2):126–41.  https://doi.org/10.1182/bloodadvances.2017011072.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Bernstein EJ, Peterson ER, Sell JL, D’Ovidio F, Arcasoy SM, Bathon JM, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314–22.  https://doi.org/10.1002/art.39021.CrossRefPubMedGoogle Scholar
  107. 107.
    Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107(12):2081–7.  https://doi.org/10.1016/j.rmed.2013.09.015.CrossRefPubMedGoogle Scholar
  108. 108.
    Sottile PD, Iturbe D, Katsumoto TR, Connolly MK, Collard HR, Leard LA, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013;95(7):975–80.  https://doi.org/10.1097/TP.0b013e3182845f23.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Crespo MM, Bermudez CA, Dew MA, Johnson BA, George MP, Bhama J, et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc. 2016;13(6):784–92.  https://doi.org/10.1513/AnnalsATS.201503-177OC.CrossRefPubMedGoogle Scholar
  110. 110.
    Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc. 2016;13(6):793–802.  https://doi.org/10.1513/AnnalsATS.201512-806OC.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139.  https://doi.org/10.1186/1471-2466-14-139.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Mortimer K, Hartmann N, Chan C, Norman H, Wallace L, Enger C. Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data. BMC Pulm Med. 2019;19(1):11.  https://doi.org/10.1186/s12890-018-0759-5.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.  https://doi.org/10.1056/NEJMoa1303006.CrossRefPubMedGoogle Scholar
  114. 114.
    Volkmann E, Tashkin D, Kuwana M, Li N, Charles J, Hant FN et al., editors. Specific pneumoproteins predict progression of interstitial lung disease in systemic sclerosis patients undergoing treatment with immunosuppression. 2018 ACR/ARHP annual meeting; 2018.Google Scholar
  115. 115.
    Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016;18(1):305.  https://doi.org/10.1186/s13075-016-1203-y.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Augustine Chung
    • 1
  • James English
    • 1
  • Elizabeth R. Volkmann
    • 1
    Email author
  1. 1.Department of Medicine, David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations